IP Library › Granted Patent US 9,067,948
Granted Patent B2
US 9,067,948 · App. 13/939,816 · Granted Jun 30, 2015

IRAK inhibitors and uses thereof

Inventors: Geraldine C. Harriman (Charlestown, RI); Ronald T. Wester (Ledyard, CT); Donna L. Romero (Chesterfield, MO); Craig E. Masse (Cambridge, MA); Shaughnessy Robinson (Westerly, RI); Jeremy Robert Greenwood (Brooklyn, NY)
Assignee: Nimbus Iris, Inc.
C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,067,948
App. No.
13/939,816
Granted
Jun 30, 2015
Kind
B2
Abstract

The present invention provides thienopyridine compounds, compositions thereof, and methods of using the same.

Claims (34)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

n is 0-4;

each R 1 is independently —R, halogen, —CN, —NO 2 , —OR, —CH 2 OR, —SR, —N(R) 2 , —S(O) 2 R, —S(O) 2 N(R) 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R) 2 , —C(O)N(R)—OR, —N(R)C(O)R, —N(R)C(O)OR, —N(R)C(O)N(R) 2 , Cy, or —N(R)S(O) 2 R; or R 1 is selected from one of the following formulas:

or

two R 1 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each Cy is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated carbocyclic ring or a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur;

each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;

Ring B is selected from a 4-8 membered partially unsaturated carbocyclic fused ring and a 4-7 membered partially unsaturated heterocyclic fused ring having 1-2 heteroatoms selected from nitrogen, oxygen, and sulfur; wherein said Ring B may be optionally substituted by one or more oxo, thiono, or imino groups;

m is 0-4;

p is 0-2;

R z is —R, —CN, —NO 2 , halogen, —C(O)N(R) 2 , —C(O)OR, —C(O)R, —N(R) 2 , —N(R)C(O)OR, —N(R)C(O)N(R) 2 , —OR, or —S(O) 2 N(R) 2 ;

R 3 is hydrogen, halogen, —CN, C 1-4 aliphatic, C 1-4 haloaliphatic, —OR, —C(O)R, or —C(O)N(R) 2 ;

L 1 is a covalent bond or a C 1-6 bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, N(R)S(O) 2 —, —S(O) 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or —S(O) 2 —;

each L 2 is independently a covalent bond or a C 1-6 bivalent hydrocarbon chain wherein one or two methylene units of the chain are optionally and independently replaced by —N(R)—, —N(R)C(O)—, —C(O)N(R)—, —N(R)S(O) 2 —, —S(O) 2 N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —S—, —S(O)— or —S(O) 2 —; and

each R 4 is independently halogen, —CN, —NO 2 , —OR, —SR, —N(R) 2 , —S(O) 2 R, —S(O) 2 N(R) 2 , —S(O)R, —C(O)R, —C(O)OR, —C(O)N(R) 2 , —N(R)C(O)R, —N(R)C(O)N(R) 2 , —C(O)N(R)OR, —N(R)C(O)OR, —N(R)S(O) 2 N(R) 2 , —N(R)S(O) 2 R, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:

two -L 2 (R 4 ) p —R 4 groups are taken together with their intervening atoms to form an optionally substituted 4-7 membered fused, spiro-fused, or bridged bicyclic ring having 0-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.

2. The compound of claim 1 , wherein said compound is of formula II:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2 , wherein said compound is of formula III:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 3 , wherein said compound is of formula IV:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 4 , wherein said compound is of formula V:

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 2 wherein m is 0.

7. The compound of claim 2 , wherein said compound is of formula XXV:

or a pharmaceutically acceptable salt thereof.

8. The compound of claim 2 , wherein said compound is of formula XXVII:

or a pharmaceutically acceptable salt thereof.

9. The compound of claim 1 , wherein said compound is selected from any one of the compounds depicted in Table 1, or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2013
From: HARRIMAN, GERALDINE C.; WESTER, RONALD T.; ROMERO, DONNA L.; MASSE, CRAIG E.; ROBINSON, SHAUGHNESSY; GREENWOOD, JEREMY ROBERT
To: NIMBUS IRIS, INC.
Reel/Frame 031049/0398 →
Continuity (3)
Provisional Application 61670380 · Jul 11, 2012
Provisional Application 61682622 · Aug 13, 2012
Related Publication 20140018357A1 · Jan 16, 2014